Monte Rosa Therapeutics, Inc. (GLUE) — 8-K Filings

8-K Filings (14)

• 8-K Filing — May 7, 2026
• 8-K Filing — Dec 16, 2025
• Monte Rosa Therapeutics Files 8-K with Material Agreement — Sep 15, 2025 Risk: medium
  On September 15, 2025, Monte Rosa Therapeutics, Inc. filed an 8-K report detailing a material definitive agreement. The filing also included Regulation FD discl
• Monte Rosa Therapeutics Files 8-K on Security Holder Vote — Jun 13, 2025 Risk: low
  Monte Rosa Therapeutics, Inc. filed an 8-K on June 13, 2025, to report on the submission of matters to a vote of its security holders. The filing does not discl
• Monte Rosa Therapeutics Files 8-K on Financials — Jan 10, 2025 Risk: low
  On January 10, 2025, Monte Rosa Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial conditio
• Monte Rosa Therapeutics Appoints New Director, Adjusts Executive Compensation — Dec 13, 2024 Risk: medium
  Monte Rosa Therapeutics, Inc. announced on December 11, 2024, changes in its board of directors and executive compensation. Specifically, Dr. Alan L. Rabinowitz
• Monte Rosa Therapeutics Files 8-K — Dec 5, 2024 Risk: low
  Monte Rosa Therapeutics, Inc. filed an 8-K on December 5, 2024, to report on various events. The filing includes information related to Regulation FD disclosure
• Monte Rosa Therapeutics Files 8-K — Oct 28, 2024 Risk: medium
  On October 25, 2024, Monte Rosa Therapeutics, Inc. entered into a material definitive agreement. The company, incorporated in Delaware with its principal execut
• Monte Rosa Therapeutics Files 8-K — Jun 27, 2024 Risk: low
  Monte Rosa Therapeutics, Inc. filed an 8-K on June 27, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not
• Monte Rosa Therapeutics Files 8-K on Security Holder Vote Matters — Jun 12, 2024 Risk: low
  On June 12, 2024, Monte Rosa Therapeutics, Inc. filed an 8-K report indicating a submission of matters to a vote of security holders. The company, incorporated
• Monte Rosa Therapeutics Appoints New CMO, Directors — May 30, 2024 Risk: low
  Monte Rosa Therapeutics, Inc. announced on May 28, 2024, the appointment of Dr. Jonathan G. Hall as Chief Medical Officer and the election of Dr. Hall and Ms. S
• Monte Rosa Therapeutics Enters Material Definitive Agreement — May 16, 2024 Risk: medium
  Monte Rosa Therapeutics, Inc. entered into a Material Definitive Agreement on May 15, 2024. The filing does not disclose the specific details of this agreement
• Monte Rosa Therapeutics Updates Executive Compensation — May 2, 2024 Risk: low
  Monte Rosa Therapeutics, Inc. announced on April 29, 2024, changes in its executive and director compensation arrangements. Specifically, the company entered in
• Monte Rosa Therapeutics Files Routine 8-K on Jan 8, 2024 — Jan 8, 2024
  Monte Rosa Therapeutics, Inc. (GLUE) filed an 8-K on January 8, 2024, primarily to disclose information under Regulation FD and to include financial statements

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX